' FDA approval of QWO is a key achievement in the continued execution of Endo's long-term strategy, especially as it relates to building our portfolio and capabilities for the future,' says Blaise Coleman, president and CEO of Endo. Food and Drug Administration (FDA) has approved collagenase clostridium histolyticum-aaes (Qwo, Endo International) for the treatment of moderate-to-severe cellulite in the buttocks in adult women, making it the first FDA-approved injectable cellulite treatment.